Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 25748654.
- Also identified by DOI 10.1016/j.cell.2015.02.038 and PMC identifier 4380877.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Genetic screens are powerful tools for identifying genes responsible for diverse phenotypes. Here we describe a genome-wide CRISPR/Cas9-mediated loss-of-function screen in tumor growth and metastasis. We mutagenized a non-metastatic mouse cancer cell line using a genome-scale library with 67,405 single-guide RNAs (sgRNAs). The mutant cell pool rapidly generates metastases when transplanted into immunocompromised mice. Enriched sgRNAs in lung metastases and late-stage primary tumors were found to target a small set of genes, suggesting that specific loss-of-function mutations drive tumor growth and metastasis. Individual sgRNAs and a small pool of 624 sgRNAs targeting the top-scoring genes from the primary screen dramatically accelerate metastasis. In all of these experiments, the effect of mutations on primary tumor growth positively correlates with the development of metastases. Our study demonstrates Cas9-based screening as a robust method to systematically assay gene phenotypes in cancer evolution in vivo.
Medical subject headings
- CRISPR-Cas Systems
- Carcinoma, Non-Small-Cell Lung
- Gene Knockout Techniques
- Lung Neoplasms
- Neoplasm Metastasis